Antibodies Archives

News and Trends 16 Nov 2016

New Private Placement to Boost the Profitable Therapeutic Antibody Market

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2016

Antibody Therapies are here to Revolutionize Dermatology

Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […]

November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Nov 2016

This Technology could Open Up a new 4th Generation of Therapeutic Antibodies

From everyday immunostaining to billion-euro therapies, antibodies have become essential in Biotech. Selecting the right antibodies that are as close to human as possible minimizes risks and can be the key to success, especially in medical applications. What goes into making the best therapeutic antibodies? To answer this question, we sat down with BIOTEM, an experienced provider of custom […]

November 1, 2016 - 5 minutesmins - By External Contributor

Sanofi regeneron rheumatoid arthritis salurimab

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

October 31, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 28 Oct 2016

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

medimmune astrazeneca cancer pd l1 nsclc trial pd l1

News and Trends 28 Oct 2016

UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer. The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of […]

October 28, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Oct 2016

UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies

Crescendo Biologics, a small UK-based startup, has made an almost €1B deal with Japanese giant Takeda for its Humabody technology. Crescendo Biologics may seem like a small fish, but it has caught the attention of a host of blue-chip investors like Sofinnova Partners. Its Humabody platform has recently attracted the Japanese pharmaceutical giant, Takeda, whose subsidiary, […]

October 11, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Oct 2016

Researchers Find New Weak Spots to Develop an HIV Cure

Last week we published a thorough review on current approaches for an HIV cure, which may be available as soon as 2020. Academia has come up with two additional strategies that could make a huge difference in the study of HIV. HIV affects 36.7 million people in the world and caused 1.1 million deaths last year. Plenty of resources […]

October 3, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

multiple sclerosis by decade3d anatomy online FI

News and Trends 15 Sep 2016

Roche’s New Antibody is besting the best MS Drug

Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab). Phase III data shows it outperforming Merck’s Rebif, the standard therapy for MS. Competition for a new MS drug has been stiff, but new promising data from the Phase III trial of Ocrevus (ocrelizumab) suggests […]

September 15, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Aug 2016

Antibodyomes for faster Discovery of Biologicals, with Memo Therapeutics

After delighting ourselves with fabulous French gastronomy in Nancy, it’s time to say our farewells and head to the next border. Basel is our final destination. Our goal? Get to know a bit more of Swiss-based company Memo Therapeutics, our Biotech of the Week. City: Basel, Switzerland Founded: 2010 Employees: 10 Financial Data: €2.1M Total Raised (as of […]

August 26, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 15 Aug 2016

Gilead licenses Danish Bispecific antibodies for the next HIV Cure

As an add-on to their previously secretive partnership, Genmab is now licensing its bispecific antibodies for Gilead‘s pursuit of an HIV cure for as much as €248M. At the top of the Pyramid of European Biotech value, Genmab is one of the success stories in Copenhagen’s Biotech ecosystem. Its technology for innovative antibodies has allowed it […]

August 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us